PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers). The purpose of this study is to investigate whether intervention from a centralized precision oncology navigator and expert review of NGS results by the precision oncology pharmacist will increase ordering of Level 1/2 genome informed therapy (GIT) compared to an estimated historical rate of 15%. Secondary endpoints will assess the impact of a centralized precision oncology navigator and expert review of NGS results on enrollment in biomarker-directed clinical trials and overall survival at 2 years after return of NGS results. The study will take approximately 12 months for enrolment and 2 years of follow-up after the date of NGS results.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana świadoma zgoda na udział w badaniu i pozwolenie na dostęp do danych zdrowotnych
- •Chęć i zdolność do uczestniczenia w procedurach badania
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Potwierdzony zaawansowany nowotwór (płuco, jelito grube, pierś lub pęcherz moczowy)
- •Lekarz uważa, że test genetyczny nowotworu jest wskazany
- •Test genetyczny nowotworu nie został jeszcze wykonany lub jest w toku
✗ Disqualifies
- •Aktywny inny nowotwór występujący jednocześnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Lineberger Comprehensive Cancer Center, University of North Carolina
Chapel Hill, United States
Trial contact
Stephanie Drotts
Douglas Kirk
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.